The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study

Hepatology ◽  
2018 ◽  
Vol 67 (6) ◽  
pp. 2244-2253 ◽  
Author(s):  
Darrick K. Li ◽  
Yanjie Ren ◽  
Daniel S. Fierer ◽  
Stephanie Rutledge ◽  
Obaid S. Shaikh ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Short Term ◽  
Hepatitis C Treatment ◽  
Direct Acting

Tumor behavior of hepatocellular carcinoma after hepatitis C treatment by direct-acting antivirals

2019 ◽  
Vol 31 (1) ◽  
pp. 75-79 ◽  
Author(s):  
Ashraf O. Abdelaziz ◽  
Mohamed M. Nabil ◽  
Ahmed H. Abdelmaksoud ◽  
Hend I. Shousha ◽  
Mohamed B. Hashem ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Hepatitis C Treatment ◽  
Direct Acting

scholarly journals Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals

Cancers ◽  
2020 ◽  
Vol 12 (11) ◽  
pp. 3414
Author(s):  
Hye Won Lee ◽  
Dai Hoon Han ◽  
Hye Jung Shin ◽  
Jae Seung Lee ◽  
Seung Up Kim ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Pegylated Interferon ◽  
Direct Acting Antivirals ◽  
Treatment Regimens ◽  
Direct Acting ◽  
Similar Risk ◽  
Carcinoma Risk

By pegylated interferon (PegIFN)-free direct-acting antivirals (DAAs) against hepatitis C virus (HCV) infection, a sustained virological response (SVR) rate >95% can be attained with a satisfactory tolerability and shorter treatment duration. However, it remains controversial whether there is any difference in prognosis depending on regimens—PegIFN or DAAs. We compared the probabilities of hepatocellular carcinoma (HCC) development between patients achieving an SVR by PegIFN/ribavirin (PegIFN group, n = 603) and DAAs (DAAs group, n = 479). The DAAs group was significantly older and had a higher proportion of cirrhosis than the PegIFN group. Before adjustment, the DAAs group had a higher HCC incidence than the PegIFN group (p < 0.001). However, by multivariate analyses, the DAAs (vs. PegIFN) group was not associated with HCC risk (adjusted hazard ratio 0.968, 95% confidence interval 0.380–2.468; p = 0.946). Old age, male, higher body mass index, cirrhosis, and lower platelet count were associated with increased HCC risk (all p < 0.05). After propensity score matching (PSM), a similar HCC risk between the two groups was observed (p = 0.372). We also compared HCC incidences according to sofosbuvir (SOF)-based and SOF-free DAAs, showing a similar risk in both groups before adjustment (p = 0.478) and after PSM (p = 0.855). In conclusion, post-SVR HCC risks were comparable according to treatment regimens; PegIFN- vs. DAA-based regimens and SOF-based vs. SOF-free DAA regimens. Further studies with a longer follow-up period are required.

868 HEPATOCELLULAR CARCINOMA INCIDENCE DECLINES AFTER WIDESPREAD INTRODUCTION OF DIRECT-ACTING ANTIVIRALS FOR HEPATITIS C

2020 ◽  
Vol 158 (6) ◽  
pp. S-179-S-180
Author(s):  
Lauren Beste ◽  
Pamela Green ◽  
Kristin Berry ◽  
Pamela S. Belperio ◽  
George N. Ioannou
Keyword(s):  
Hepatocellular Carcinoma ◽  
Hepatitis C ◽  
Direct Acting Antivirals ◽  
Direct Acting
Sign in / Sign up

Export Citation Format

Share Document